AR122587A1 - Compuestos de imidazopiridazina y sus usos - Google Patents
Compuestos de imidazopiridazina y sus usosInfo
- Publication number
- AR122587A1 AR122587A1 ARP210101581A ARP210101581A AR122587A1 AR 122587 A1 AR122587 A1 AR 122587A1 AR P210101581 A ARP210101581 A AR P210101581A AR P210101581 A ARP210101581 A AR P210101581A AR 122587 A1 AR122587 A1 AR 122587A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- azabicyclo
- methyl
- formula
- imidazopyridazine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Dental Preparations (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038410P | 2020-06-12 | 2020-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122587A1 true AR122587A1 (es) | 2022-09-21 |
Family
ID=76971994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101581A AR122587A1 (es) | 2020-06-12 | 2021-06-10 | Compuestos de imidazopiridazina y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11840546B2 (https=) |
| EP (1) | EP4165051A1 (https=) |
| JP (1) | JP2023530088A (https=) |
| KR (1) | KR20230025434A (https=) |
| CN (1) | CN115956081A (https=) |
| AR (1) | AR122587A1 (https=) |
| AU (1) | AU2021288107A1 (https=) |
| BR (1) | BR112022025191A2 (https=) |
| CA (1) | CA3184811A1 (https=) |
| CL (1) | CL2022003453A1 (https=) |
| CO (1) | CO2022017969A2 (https=) |
| EC (1) | ECSP22093652A (https=) |
| IL (1) | IL298248A (https=) |
| MX (1) | MX2022015493A (https=) |
| PE (1) | PE20230491A1 (https=) |
| TW (1) | TWI895442B (https=) |
| WO (1) | WO2021252781A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| ATE522249T1 (de) * | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| AR068877A1 (es) | 2007-10-17 | 2009-12-09 | Novartis Ag | Derivados heterociclicos de imidazol |
| CA2806655A1 (en) | 2010-07-28 | 2012-02-02 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-b]pyridazines |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| CA2834901A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| WO2014160203A2 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20190218214A1 (en) | 2016-09-14 | 2019-07-18 | Vanderbilt University | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof |
| MX2019002951A (es) | 2016-09-15 | 2019-09-11 | Armstrong World Ind Inc | Sistema de techo con movimiento aereo. |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| WO2018136634A1 (en) | 2017-01-18 | 2018-07-26 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods |
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
-
2021
- 2021-06-10 CA CA3184811A patent/CA3184811A1/en active Pending
- 2021-06-10 CN CN202180041015.0A patent/CN115956081A/zh active Pending
- 2021-06-10 MX MX2022015493A patent/MX2022015493A/es unknown
- 2021-06-10 WO PCT/US2021/036839 patent/WO2021252781A1/en not_active Ceased
- 2021-06-10 AR ARP210101581A patent/AR122587A1/es unknown
- 2021-06-10 BR BR112022025191A patent/BR112022025191A2/pt unknown
- 2021-06-10 AU AU2021288107A patent/AU2021288107A1/en not_active Withdrawn
- 2021-06-10 IL IL298248A patent/IL298248A/en unknown
- 2021-06-10 PE PE2022002872A patent/PE20230491A1/es unknown
- 2021-06-10 TW TW110121255A patent/TWI895442B/zh active
- 2021-06-10 EP EP21743321.8A patent/EP4165051A1/en active Pending
- 2021-06-10 JP JP2022576034A patent/JP2023530088A/ja not_active Ceased
- 2021-06-10 KR KR1020237000999A patent/KR20230025434A/ko active Pending
- 2021-06-10 US US17/344,255 patent/US11840546B2/en active Active
-
2022
- 2022-12-06 CL CL2022003453A patent/CL2022003453A1/es unknown
- 2022-12-09 EC ECSENADI202293652A patent/ECSP22093652A/es unknown
- 2022-12-12 CO CONC2022/0017969A patent/CO2022017969A2/es unknown
-
2023
- 2023-10-31 US US18/385,742 patent/US20240083918A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN115956081A (zh) | 2023-04-11 |
| JP2023530088A (ja) | 2023-07-13 |
| WO2021252781A1 (en) | 2021-12-16 |
| CA3184811A1 (en) | 2021-12-16 |
| IL298248A (en) | 2023-01-01 |
| EP4165051A1 (en) | 2023-04-19 |
| US20240083918A1 (en) | 2024-03-14 |
| KR20230025434A (ko) | 2023-02-21 |
| ECSP22093652A (es) | 2023-02-28 |
| AU2021288107A1 (en) | 2022-12-15 |
| US20210388003A1 (en) | 2021-12-16 |
| CO2022017969A2 (es) | 2023-02-27 |
| US11840546B2 (en) | 2023-12-12 |
| CL2022003453A1 (es) | 2023-05-26 |
| BR112022025191A2 (pt) | 2023-03-07 |
| TW202214660A (zh) | 2022-04-16 |
| TWI895442B (zh) | 2025-09-01 |
| MX2022015493A (es) | 2023-03-21 |
| PE20230491A1 (es) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127235A1 (es) | Pirazoloquinolinas inhibidoras de kras | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| AR133266A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| AR133199A1 (es) | Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias | |
| CL2025000529A1 (es) | Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer. | |
| AR097773A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| AR122587A1 (es) | Compuestos de imidazopiridazina y sus usos | |
| CO2025004701A2 (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| PE20241186A1 (es) | Compuestos de cd73 |